Weekly Rundown: Small-Cap Stocks with Upcoming Catalysts (May 12–16)

We have combed through recent disclosures and company announcements to bring you the most relevant small-cap events and investor conferences this week. Our goal is to keep you informed about key developments—before the rest of the market catches on. Here’s what we’re watching from May 12 through May 16.

Companies presenting at American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting May 13–17, 2025 | New Orleans, LA:

ARTV: The company will have a poster presentation on new longer-term Phase 1/2 data for AlloNK® (also known as AB-101) in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

PRQR: The company will present multiple abstracts, including an oral presentation titled "ADAR-Mediated RNA Editing of SLC10A1 (NTCP) as a Therapeutic Approach to Reduce Liver Bile Acid Re-Uptake in Cholestatic Diseases." Additional poster presentations include "ADAR-Mediated RNA Editing-Based Correction of PNPLA3|148M Functionality to Address Hepatic Steatosis" and "ADAR-Mediated RNA Editing of Premature Termination Codon Results in Functional Correction in MECP2 for Rett Syndrome."

VYGR: The company will deliver eight oral and poster presentations.

FATE: Five presentations of clinical and preclinical data from the company’s induced pluripotent stem cell (iPSC) product platform will be featured.

IPSC: The company announced two presentations: one on arming iPSC-derived allogeneic therapies with a TGF-beta neutralizing synthetic receptor that enhances solid tumor elimination in TME-mimicking conditions in vitro, and another on the generation of iPSC-derived CD4+ and CD8+ CD19 CAR alpha-beta T cells showing in vivo tumor control and cell expansion comparable to healthy donor T cells.

CLLS: The company will unveil research on TALEN®-mediated non-viral transgene insertion for advancing gene and cell therapies, along with advancements using TALE base editors (TALEB).

DTIL: Five abstracts detailing Precision's wholly owned or partnered programs have been accepted.

INO: The company will present a poster titled "Successful Treatment of Recurrent Respiratory Papillomatosis with INO-3107 is Irrespective of Papilloma Microenvironment and Molecular Subtype."

MGX: The company will present three poster presentations.

ACET: The company will deliver an oral abstract highlighting strong preclinical data demonstrating ADI-270's anti-tumor activity in both hematologic and solid tumor models.

LXEO: New data supporting the company’s AAV manufacturing platform will be presented.

SLDB: The company will share data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy for Duchenne muscular dystrophy.

INAB: The company will present a poster titled "INB-600: A Novel T Cell Engager Platform Specific for Gamma-Delta (γδ) T Cells."

GNPX: The company will present the abstract "Immune Modulation Sustains Alpha Cell Reprogramming and Mitigates Immune Responses to AAV in a Diabetic Non-Human Primate Model."

EDIT: The company will share new preclinical data confirming its ability to increase protein levels using its gene upregulation editing strategy to address loss-of-function diseases.

TCRX: The company will present research titled "CD45 as a Universal Target for Adjuvant TCR-T Cell Therapy Following Allogeneic Hematopoietic Cell Transplantation."

GUTS: The company will deliver an oral presentation featuring compelling preclinical data from its Rejuva single-administration Smart GLP-1 pancreatic gene therapy platform.

CAMP: The company will present on targeting regulatory RNAs with antisense oligonucleotides for urea cycle disorders, and will also share interim safety results from a first-in-human, double-blind, placebo-controlled study evaluating CMP-CPS-001 in healthy volunteers.

SGMO: The company will deliver oral presentations showcasing its zinc finger repressors (ZFRs) as a new class of epigenetic regulators for neurological diseases. Presentations include data on combining a prion gene-targeting ZFR with STAC-BBB, its IV-administered neurotropic capsid, for the treatment of prion disease.

Companies presenting at the Bank of America Global Healthcare Conference 2025 (May 13–15, Las Vegas, NV):

RLAY AMLX ABOS STRO FDMT IMTX ADGM ERAS CRBU ALEC RXRX CADL TCRX EDIT LUNG CATX NSPR AVAH CLOV AGL

Companies participating at the D. Boral Capital Inaugural Global Conference at The Plaza Hotel in New York City on May 14, 2025. The conference will feature Kevin O’Leary, widely known as “Mr. Wonderful” from ABC’s hit show Shark Tank, as the keynote speaker:

MOGO ERNA SSKN XHLD GNTA PSTV CNTX WKSP RADX SUUN TTI IVP FLYE KAPA NOTE ZENA NMTC SKYQ NNVC

Companies presenting at the 4th Annual ALS Drug Development Summit taking place May 12–14, 2025, in Boston, Massachusetts:

ATHA: Will be presenting Phase 1 and nonclinical efficacy data for ATH-1105 for the potential treatment of ALS

BCLI: The company's senior leadership team will participate in sessions that highlight insights and expertise gained throughout the NurOwn® development program, contributing to the broader conversation on the future of ALS clinical research.

Companies presenting at the 6th Annual Cytokine-Based Drug Development Summit taking place May 15–16, 2025, in Boston:

INDP: Chief Scientific Officer Dr. Newman will deliver a presentation titled "Pulsed Cytokine Delivery for Anti-Tumor Immunotherapy & its Impact on Toxicity & Efficacy" on Thursday, May 15 at 12:15PM ET. He will also lead a panel discussion on pre-clinical models for cytokine drug development and deliver opening and closing remarks on Day 2 of the conference.

SONN: Title: Managing Toxicity Caused by The Over Expression of Cytokines to Widen the Therapeutic Window.

Companies participating at the J.P. Morgan 53rd Annual Global Technology, Media and Communications Conference on May 13–15, 2025, in Boston, MA:

CCO RSKD EB UNIT WULF

Companies participating at the Needham & Co. 20th Annual Technology, Media & Consumer Conference – May 12 & 13, 2025, at the InterContinental New York Times Square in New York City:

NOTE GCI TLS RBBN BMR

Companies presenting at the 2025 Combined Otolaryngology Spring Meetings (COSM), taking place May 14–18, 2025, in New Orleans, Louisiana:

BDMD: Baird Medical's participation in COSM highlights the expanding applications and growing interest of its advanced microwave ablation (MWA) technology within the diverse field of otolaryngology.

LYRA: The company plans to present results from the 52-week Extension Stage of the ENLIGHTEN 1 Phase 3 study for LYR-210, the company's lead product candidate for chronic rhinosinusitis (CRS).

INO: Oral Presentation: DNA Immunotherapy (INO-3107) Durability and Long-Term Clinical Effect in Treatment of Recurrent Respiratory Papillomatosis Caused by HPV 6 & 11.

Companies participating at the H.C. Wainwright 1st Annual Royalty Company Virtual Conference, taking place on Tuesday, May 13, 2025:

OABI FBIO

Companies presenting at the 21st Annual PEGS Boston Summit, taking place May 12-16 at the Omni Boston Hotel at the Seaport:

STTK: Taylor Schreiber, M.D., Ph.D., CEO of Shattuck Labs, will present on SL-325 in the Advances in Immunotherapy section of the conference.

OABI: OmniAb will showcase xPloration, a high-throughput single B-cell screening instrument that uses machine learning and AI to address challenges in traditional B-cell screening, such as limited antibody diversity and lengthy processes.

Companies participating at the BMO Global Farm to Market Conference - May 14-15, 2025 in New York, NY:

GRO ZVIA

Other companies with key Catalysts this week:

NB: Executive Chairman & CEO Mark Smith and COO Scott Honan will present at the 121 Mining Investment Conference (May 12–13, London) and participate in the 2025 Defense Conference by Aviation Week (May 13–14, Washington, D.C.).

ACRS: CEO Neal Walker and Aclaris leadership team will join a virtual fireside chat during the HC Wainwright "HCW@Home" series on Friday, May 16, 2025, at 1:00 PM EDT.

TBLA: Will participate in the Seaport Growth Conference on May 15, 2025, with a fireside chat scheduled for 1:00 p.m. ET.

HSCS: Will host a live investor webinar on Wednesday, May 14, 2025, at 2:00 p.m. EDT | 11:00 a.m. PDT, featuring a presentation and Q&A session with CEO Andrew Simpson.

CUE: Will host a virtual investor event on Thursday, May 15, 2025 at 11:00 AM ET.

BOLT: Will host a KOL conference call and webcast on May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET, featuring Dr. Ecaterina Dumbrava of MD Anderson Cancer Center, an investigator in the Phase 1 study of BDC-3042.

AMLX: Will participate at the Bank of America 2025 Health Care Conference: Fireside chat on Tuesday, May 13, 2025, at 1:55 p.m. PT in Las Vegas, Nevada.

SERA: Expects to have a strong presence at the ACOG 2025 Annual Clinical & Scientific Meeting (May 16–18), where it plans to engage attendees and encourage continued investigator-initiated research on its PreTRM test-and-treat paradigm.

VANI: CEO Adam Mendelsohn, Ph.D., will present and participate in a panel discussion at the American Association of Pharmaceutical Scientists' (AAPS) "Beyond GLP1s: Where the Science will Take Business Next" Virtual Workshop, taking place from May 13-14, 2025.

AVIR: Following the EASL Congress 2025, Atea will host a virtual key opinion leader (KOL) investor event with a panel of HCV experts and prescribers on Wednesday, May 14, 2025, at 10:00 AM ET.

EGY: Will host its Capital Markets Day presentation on Wednesday, May 14, 2025, from 8:00–10:00 a.m. CT (2:00–4:00 p.m. London Time). The event, open to shareholders, analysts, and institutional investors, will be webcast live with Q&A and presentation materials available.

BITF: Will participate in Consensus 2025, taking place May 14–16 in Toronto, Ontario, with speakers including CEO Ben Gagnon, CFO Jeff Lucas, SVP of Mining Operations Alex Brammer, and General Counsel for North America Rachel Silverstein.

CBAT: Will participate in the upcoming Shenzhen International Battery Technology Conference & Expo (CIBF 2025), scheduled for May 15–17, 2025.

IMUX: Kimi Oanh Le, Head of Clinical Trial Supply at Immunic, will speak on clinical trial supply chain challenges in the Middle East and North Africa (MENA) at the Clinical Trial Supply Forum 2025, taking place May 13–15 in Brussels, Belgium.

SLRN / ALMS: The Company's special meeting of stockholders to vote on the Proposed Transaction (proposed merger) is scheduled for May 13, 2025. ACELYRIN urges its stockholders to vote FOR the Proposed Transaction today.

SCLX: Will present a post-hoc analysis of the C.L.E.A.R. trial, evaluating the safety and efficacy of SP-102 (SEMDEXA™) for lumbosacral radicular pain, at the 27th Annual Meeting of the American Society of Interventional Pain Physicians (ASIPP), taking place May 15–17, 2025, in Orlando, FL.

PALI: Has been selected to give an oral presentation at the3rdAnnual Precision Medicine in Inflammatory Bowel Disease Summit being held May 13–15, 2025 in Boston, MA.

TVGN: CEO Dr. Ryan Saadi, MD, MPH, will participate in BioNJ's Fifteenth Annual Bio Partnering Conference on May 13, 2025, at The Liberty Science Center in Jersey City, NJ, where he will join the panel discussion “Paths to Liquidity: Strategies for Adapting to a Volatile Market,” moderated by David C. Schwartz of Morgan Lewis.

SKYE: European Congress on Obesity (Malaga, Spain) Poster presentation, May 13.

LAES: Will host the French Quantum and Space Day on May 12–13, 2025, at Hotel Le Fregate in Saint-Cyr-sur-Mer, France, bringing together global experts to explore quantum computing, cybersecurity, and space infrastructure for protecting data against emerging quantum threats.

ICON: Board of Directors approved a cash dividend of $0.07 per common share for the fourth quarter of 2024. The cash dividend will be paid on or around May 30, 2025, to all common shareholders of record as of May 16, 2025.

LIPO: LP-10 data for treating Oral Lichen Planus will be presented by Dr. Alessandro Villa on May 15 at the 2025 AAOM/EAOM meeting in Las Vegas.

SHLS: will participate in the UBS Energy Transition and Decarbonization Conference on May 13, 2025, in New York, with VP of Finance & IR Matt Tractenberg hosting investor meetings. On May 14–15, CFO Dominic Bardos and Tractenberg will join analyst Joe Osha for investor meetings during the Guggenheim Non-Deal Roadshow in Los Angeles and the San Francisco Bay Area.

BJDX: Will present an abstract on its lead product candidate, the Symphony IL-6 Test, at the Society of Academic Emergency Medicine (SAEM) Annual Meeting in Philadelphia, May 13–16, 2025. The presentation will share results from the SYMON-I pilot study evaluating IL-6 in sepsis patients as a prognostic tool for 28-day mortality and exploratory outcomes.

TPET: On April 4, 2025, Trio Petroleum Canada entered into an agreement to acquire oil and gas assets from Novacor Exploration in the Lloydminster, Saskatchewan region for $650,000 and 526,536 shares of common stock. The acquisition is structured in two closings, with the first completed on April 8 and the second expected on or after May 15, 2025, pending certain conditions.

JUNS: We have applied for a $16.5 million NIH grant to support a Phase II trial for MCI/early Alzheimer's, with funding potentially available for a three-year trial starting in late 2025. A decision on NIH funding for the JNS108 Alzheimer's study is expected in May 2025.

IPDN: The company has been recognized as a finalist for two prestigious Digital Job Advertising Excellence (DJAx) Awards: the Technology Innovation Award and Best Customer Success Team Award in the niche job board category. The DJAx Awards ceremony will be held in London on May 15, 2025.

MRSN: Phase 1 dose escalation and backfill cohort clinical data for emiltatug ledadotin (Emi-Le; XMT-1660) will be presented in an oral session at the ESMO Breast Cancer 2025 Annual Congress, which is being held from May 14-17, 2025, in Munich, Germany.

EYEN: On March 18, 2025, Eyenovia and Betaliq entered a non-binding letter of intent for a reverse merger, where Betaliq will become a wholly-owned subsidiary of Eyenovia. Eyenovia plans to change its name to "Betaliq, Inc." after the merger. The parties have an exclusivity period until May 16, 2025, to finalize the agreement.

--

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.